Concord Drugs (BOM:538965) Net Interest Income: ₹-17.1 Mil (TTM As of Mar. 2026)


BOM:538965 Concord Drugs Ltd BOM:538965
57 GF Score
Price ₹76.05
GF Value ₹60.38
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Concord Drugs Net Interest Income?

Concord Drugs BOM:538965 -0.11% 57 Net Interest Income is ₹-17.1 Mil as of Mar. 2026. GuruFocus rates BOM:538965 with a GF Score™ of 57/100 and a GF Value™ of ₹60.38 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Concord Drugs's net interest income for the three months ended in Mar. 2026 was ₹-4.0 Mil. Its net interest income for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-17.1 Mil.

Concord Drugs Net Interest Income Related Terms

Concord Drugs Net Interest Income Historical Data

* Premium members only.

The historical data trend for Concord Drugs's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Concord Drugs Net Interest Income Chart

Concord Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Net Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.66 -17.95 -19.09 -20.27 -17.14

Concord Drugs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.11 -4.90 -4.88 -3.40 -3.96
BOM:538965
57GF Score
Concord Drugs Ltd BOM:538965
Net Interest Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Concord Drugs Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-17.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Interest Income →
What does a Net Interest Income of ₹-17.1 Mil mean?
Concord Drugs (BOM:538965) has a Net Interest Income of ₹-17.1 Mil as of Mar. 2026.
Is Concord Drugs' Net Interest Income too high?
Concord Drugs' current Net Interest Income is ₹-17.1 Mil. Overall, Concord Drugs has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Concord Drugs' Net Interest Income compare to ZTS?
Concord Drugs' Net Interest Income of ₹-17.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Interest Income for a Drug Manufacturers company?
A good Net Interest Income depends on the Drug Manufacturers industry context. However, Net Interest Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Interest Income mean?
A high Net Interest Income can signal that a stock is expensive relative to its fundamentals. Concord Drugs's current Net Interest Income is ₹-17.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Drugs stock overvalued right now?
Based on GuruFocus' analysis, Concord Drugs (BOM:538965) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹60.38, compared to a current price of ₹76.05 — trading 26% above its estimated fair value. The current Net Interest Income is ₹-17.1 Mil. Concord Drugs' overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Interest Income calculated?
Net Interest Income is calculated from a company's financial statements. For Concord Drugs (BOM:538965), the current Net Interest Income is ₹-17.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Concord Drugs (BOM:538965) Overvalued in 2026?

Based on GuruFocus' analysis, Concord Drugs stock appears to be overvalued. The current stock price of ₹76.05 is trading 26% above its estimated GF Value™ of ₹60.38. GuruFocus considers Concord Drugs to be Modestly Overvalued.

Key valuation signals for BOM:538965:

  • Net Interest Income: ₹-17.1 Mil
  • GF Value™: ₹60.38 vs. price of ₹76.05 (26% above fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the BOM:538965 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Concord Drugs Business Description

Address Survey No. 249, Brahmanapally Village, Hayatnagar Mandal, Ranga Reddy, Hyderabad, TG, IND, 501511
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers.
57GF Score

Get the complete analysis for BOM:538965

Net Interest Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹76.05
Price
₹60.38
GF Value